13268-73-0

Basic information

• Product Name: 1H-Purin-6-amine, N-[(2-methylphenyl)methyl]-
• CAS NO: 13268-73-0
• Molecular Formula: C13H13N5
• Molecular Weight: 239.28
• Mol File: 13268-73-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Purin-6-amine, N-[(2-methylphenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Purin-6-amine, N-[(2-methylphenyl)methyl]-(13268-73-0)
• EPA Substance Registry System: 1H-Purin-6-amine, N-[(2-methylphenyl)methyl]-(13268-73-0)

Safety Data

• Hazardous Substances Data: 13268-73-0(Hazardous Substances Data)

Usage

Compound group

Purine derivatives.

Receptor selectivity

Selective antagonist of adenosine A1 receptors.

Usage

Commonly used in biochemical research.

Potential applications

Development of pharmaceuticals and drugs targeting adenosine receptors.

Physiological role

Adenosine receptors play a crucial role in various physiological processes in the human body.

Cancer therapy

Studied for its potential role as an anticancer agent, with the ability to inhibit the growth of cancer cells.

Versatility

Has potential applications in various fields, including pharmacology and medicine.

Upstream product

• 100728-74-3 N-(7⁽⁹⁾H-purin-6-yl)-o-toluamide 
• 89-93-0 ortho-methylbenzylamine 
• 87-42-3 6-chloro-7H-purine 
• 87-42-3 6-chloropurine 
• 607-86-3 2-methylbenzoic anhydride 
• 73-24-5 7H-purin-6-ylamine 
• 50-66-8 6-(methylthio)-1H-purine 

Relevant articles and documents

Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)

The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.

Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells

To study the structure-activity relationships of aromatic cytokinins, the cytokinin activity at both the receptor and cellular levels, as well as CDK inhibitory and anticancer properties of 38 6-benzylaminopurine (BAP) derivatives were compared in various